Amani Al Shaban RPh, M.Sc Pharm, Pharmacy Director,Saud Albabtain Cardiac Center.KSA


An increased prevalence of cardiovascular disease (CVD) has been found in women of childbearing age, and Up to 4% of pregnancies may have cardiovascular complications despite no known prior disease. With the presence of CVD in pregnant women posing a difficult clinical scenario in which the responsibility of the treating physician extends to the unborn fetus. When a woman uses medication, she needs to be advised about the continuation, cessation or change of her medication before she gets pregnant. Medication classes like statins and anticoagulants are part of the medication treatment plan for most of the CVD and as it’s known to be contraindicated during pregnancy challenges the treating physician to find the best possible alternative weighing the risk over benefit and considering new drug classes like PCSK9 inhibitors as an alternative therapy for statins and using new oral anticoagulants like rivaroxaban is still questionable and opening new challenges for the physician and clinical pharmacists to study the effect of use in pregnant women and consider it in the treatment plan.



  • Highlights the importance of weighing the risk over benefit and the difficulties that the physician face when treating pregnant women with cardiovascular diseases.
  • Discuss how the education for patients with cardiovascular diseases before and during pregnancy can play a big role in decreasing the risk of harm from the medication.
  • To discuss the possibility of considering new medications like PCSK9 inhibitors and rivaroxaban as alternative therapy during pregnancy.